Iron Triangle Partners LP Neurocrine Biosciences Inc Transaction History

Iron Triangle Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $2.62 Million - $2.86 Million	-20,000 Reduced 9.09%	200,000 $27.5 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $28.7 Million - $31.6 Million	220,000 New	220,000 $30.3 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $27.3 Million - $32.5 Million	-255,512 Reduced 71.85%	100,089 $12 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $515,460 - $603,843	5,601 Added 1.6%	355,601 $37.8 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $26.5 Million - $35 Million	350,000 New	350,000 $34.1 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Iron Triangle Partners LP, based on Form 13F filings with the SEC.

Stay updated on Iron Triangle Partners LP with notifications on news.